Jan Eriksson - Dissemin

All papers authored by Jan Eriksson

This paper was not found in any repository, but could be made available legally by the author.

2020 Skander Mulder

, Ann Hammarstedt, Sunil B. Nagaraj

, Viji Nair, Wenjun Ju

, Jonatan Hedberg, Peter J. Greasley, Jan W. Eriksson

, Jan Oscarsson, Hiddo J. L. Heerspink

A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

Upload

This paper is made freely available by the publisher.

2019 Anna Norhammar

, Johan Bodegård

, Thomas Nyström

, Marcus Thuresson

, David Nathanson

, Jan W. Eriksson

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study

Download from api.wiley.com

Petros Katsogiannos

, Prasad G. Kamble

, Gretha J. Boersma

, F. Anders Karlsson, Per Lundkvist

, Magnus Sundbom

, Maria J. Pereira

, Jan W. Eriksson

Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Upload

2018 Frederik Persson, Johan Bodegard

, Jorma T. Lahtela, Thomas Nyström, Marit E. Jørgensen, Majken Linneman Jensen, Hanne L. Gulseth, Marcus Thuresson, Fabian Hoti, David Nathanson, Anna Norhammar

, Kåre I. Birkeland

, Johan G. Eriksson, Jan W. Eriksson

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

Download from doi.org

Per Lundkvist

, Maria J. Pereira

, Prasad G. Kamble

, Petros Katsogiannos

, Anna Maria Langkilde, Russell Esterline, Eva Johnsson, Jan W. Eriksson

Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes

Upload

Maria J. Pereira, Per Lundkvist, Prasad G. Kamble

, Joey Lau

, Julian G. Martins, C. David Sjöström, Volker Schnecke, Anna Walentinsson, Eva Johnsson, Jan W. Eriksson

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Download from link.springer.com

Matthew A. Cavender, John P. Wilding, Thomas Nyström, Alex Z. Fu, Marcus Thuresson, Johan Bodegård

, Kamlesh Khunti

, Eric Wittbrodt, Reinhard W. Holl, David Nathanson

, Kåre I. Birkeland

, Anna Norhammar

, Marit Eika Jørgensen

, Niklas Hammar, Peter Fenici and 2 other authors

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6–10

Download from diabetesjournals.org

2017 Thomas Nyström, Johan Bodegard

, David Nathanson, Marcus Thuresson, Anna Norhammar

, Jan W. Eriksson

Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Download from api.wiley.com

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Jan Eriksson